Loading...
Indian Pharmaceutical Exporter · #5 for Secnidazole · $200.0K export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Secnidazole with $200.0K in export value and 4 verified shipments. Cipla Limited holds a 0.7% market share in Secnidazole exports across 1 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| YEMEN | $400.0K | 8 | 3.8% |
| NIGERIA | $374.9K | 17 | 3.5% |
| VENEZUELA | $353.8K | 35 | 3.3% |
| GHANA | $317.6K | 25 | 3.0% |
| UGANDA | $290.1K | 26 | 2.7% |
| UKRAINE | $165.0K | 19 | 1.6% |
India exports Secnidazole to 77 countries. The top destination is FRANCE (33.1%), followed by GUATEMALA and TANZANIA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NUEVOS ETICOS NEOETHICALS, S.A. | GUATEMALA | $1.5M | 30 |
| PLANET PHARMA SA | FRANCE | $900.0K | 18 |
| HEKO PHARMACY LTD | TANZANIA | $450.0K | 9 |
| PIEX SOCIETE PHARMACEUTIQUE | FRANCE | $430.0K | 12 |
| NUEVOS ETICOS NEOETHICALS S A | GUATEMALA | $363.3K | 9 |
| PLANET PHARMA | FRANCE | $250.0K | 5 |
| CLARION MEDICALS LIMITED | NIGERIA | $250.0K | 5 |
| PIEX SOCIETE PHARMACEUTIQUE, | FRANCE | $240.8K | 7 |
| MEDICA PHARMACEUTICAL INDUSTRIES LI | YEMEN | $200.0K | 4 |
| TO THE NAME OF SOCIETE GENERALE | ALGERIA | $100.0K | 2 |
India's Secnidazole is purchased by 239 buyers worldwide. The top buyer is NUEVOS ETICOS NEOETHICALS, S.A. (GUATEMALA), followed by PLANET PHARMA SA and HEKO PHARMACY LTD.
India exported $8.9M worth of Secnidazole through 652 shipments from 115 suppliers to 77 countries, serving 239 buyers globally. Cipla Limited contributes $200.0K to this total, accounting for 0.7% of India's Secnidazole exports.
Cipla Limited's average Secnidazole shipment value is $50.0K per consignment, based on 4 shipments totaling $200.0K.
Cipla Limited ranks #5 among 115 Indian Secnidazole exporters with a 0.7% market share. The top 3 exporters are CAPLIN POINT LABORATORIES LIMITED ($2.1M), AJANTA PHARMA LIMITED ($2.0M), LINCOLN PHARMACEUTICALS LTD ($950.0K). Cipla Limited processed 4 shipments to 1 destination countries.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | NIYA HEALTHCARE PRIVATE LIMITED | $250.0K | 5 | 1 | $50.0K |
| 9 | THE MADRAS PHARMACEUTICALS | $250.0K | 5 | 1 | $50.0K |
| 5 | CIPLA LIMITED ★ | $200.0K | 4 | 1 | $50.0K |
| 11 | ZEST PHARMA | $192.9K | 14 | 6 | $13.8K |
| 12 | ALICE PHARMA PRIVATE LIMITED | $187.1K | 11 | 2 | $17.0K |
Cipla Limited ranks #5 among 115 Indian Secnidazole exporters. Average shipment value of $50.0K compared to the market average of $77.0K. The closest competitors by value are NIYA HEALTHCARE PRIVATE LIMITED and THE MADRAS PHARMACEUTICALS.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 75 | 11.5% |
| SAHAR AIR | 59 | 9.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 57 | 8.7% |
| JNPT/ NHAVA SHEVA SEA | 46 | 7.1% |
| DELHI AIR | 46 | 7.1% |
| JNPT | 34 | 5.2% |
| DELHI AIR CARGO ACC (INDEL4) | 31 | 4.8% |
| AHEMDABAD ICD | 22 | 3.4% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Secnidazole, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Secnidazole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 77+ countries, 239+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Secnidazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Secnidazole. For current shipment-level data, contact TransData Nexus.